Chikanza I C, Clarke B, Hopkins R, MacFarlane D G, Bird H, Grahame R
Department of Rheumatology, United Medical School, Guy's Hospital, London.
Br J Clin Pract. 1994 Mar-Apr;48(2):67-9.
In a two-period, double-blind, crossover study, patients with osteoarthritis of the knee and/or hip received etodolac 300 mg twice daily for 4 weeks and naproxen 500 mg twice daily for 4 weeks in random order. The assessment of efficacy showed that naproxen and etodolac were equally effective in the management of pain and stiffness in osteoarthritis. However, a significantly higher proportion of patients preferred naproxen to etodolac for the relief of pain intensity. The incidence of adverse events caused by either drug was the same.